John McLennan - Amdocs Independent Director
| DOX Stock | USD 85.11 0.18 0.21% |
Director
Mr. John T. McLennan, Ph.D., is Independent Director of Amdocs Limited. Mr. McLennan was a director of Amdocs since 1999 and is Chairman of the Management Resources and Compensation Committee. From 2000 until 2004, he served as ViceChair and Chief Executive Officer of Allstream . Mr. McLennan founded Jenmark Consulting Inc. and was its President from 1997 until 2000. From 1993 to 1997, Mr. McLennan served as the President and Chief Executive Officer of Bell Canada. Prior to that, he held various positions at several telecommunications companies, including BCE Mobile Communications and Cantel Inc. Mr. McLennan is also a director of Emera Inc., a Canadian publiclyheld energy services company, and was its Chairman from 2009 to 2014. since 1999.
| Age | 71 |
| Tenure | 25 years |
| Professional Marks | Ph.D |
| Address | 625 Maryville Centre Drive, Saint Louis, MO, United States, 63141 |
| Phone | 314 212 7000 |
| Web | https://www.amdocs.com |
Amdocs Management Efficiency
The company has Return on Asset of 0.071 % which means that on every $100 spent on assets, it made $0.071 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1562 %, implying that it generated $0.1562 on every 100 dollars invested. Amdocs' management efficiency ratios could be used to measure how well Amdocs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.10 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Amdocs' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 307 M in 2024, whereas Total Assets are likely to drop slightly above 4.5 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Francois Auque | CyberArk Software | 61 | |
| Eric Duprat | Wex Inc | 55 | |
| Yoav Chelouche | Check Point Software | 65 | |
| Michel Combes | F5 Networks | 56 | |
| Pamela Craig | Akamai Technologies | 61 | |
| Pamela Bailey | Global Blue Group | 65 | |
| Frank Sica | CSG Systems International | 67 | |
| John Hughes | CSG Systems International | 64 | |
| Kathleen Cote | VeriSign | 69 | |
| Susan Sobbott | Wex Inc | 55 | |
| William Summers | Global Blue Group | 64 | |
| Jean Hobby | Global Blue Group | N/A | |
| Shai Weiss | Check Point Software | N/A | |
| Daniel Callahan | Wex Inc | 63 | |
| Rajan Naik | CSG Systems International | 46 | |
| David Rubner | Check Point Software | 76 | |
| Ping Wai | Global Blue Group | N/A | |
| Donald Smith | CSG Systems International | 75 | |
| Raphael Kesten | CyberArk Software | 60 | |
| Teresita Loubriel | Evertec | 64 | |
| Ronald Maheu | Wex Inc | 72 | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.071 |
Amdocs Leadership Team
Elected by the shareholders, the Amdocs' board of directors comprises two types of representatives: Amdocs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amdocs. The board's role is to monitor Amdocs' management team and ensure that shareholders' interests are well served. Amdocs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amdocs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua Sheffer, CEO President | ||
| Darcy Antonellis, Head Media | ||
| Oren Marmur, Head Network | ||
| Richard LeFave, Independent Director | ||
| Matthew Smith, Corporate Secretary | ||
| John MacDonald, Director | ||
| Idit Aronsohn, Inclusion Responsibility | ||
| Zohar Zisapel, Independent Director | ||
| Simon Olswang, Independent Director | ||
| Anshoo Gaur, Division President of Amdocs Devel. Center India Pvt Ltd | ||
| Elizabeth McDermon, Secretary and VP of Corporate Strategy of Amdocs Inc. | ||
| Giora Yaron, Director | ||
| Gary Miles, Chief Officer | ||
| Shuky Sheffer, Senior Vice President and President of Customer Business Group, Amdocs Management Limited | ||
| Robert Minicucci, Independent Chairman of the Board | ||
| Mustafa Oyumi, Head Strategy | ||
| Clayton Christensen, Director | ||
| James Kahan, Independent Director | ||
| Rajat Raheja, Division President Amdocs Development Center India Pvt. Ltd | ||
| Avishai Sharlin, GM President | ||
| Adrian Gardner, Independent Director | ||
| Tamar RapaportDagim, Senior Vice President and CFO of Amdocs Management Limited | ||
| John McLennan, Independent Director | ||
| Matt Smith, IR Contact Officer | ||
| Julian Brodsky, Independent Director | ||
| Anthony Goonetilleke, Group Strategy | ||
| Eli Gelman, Director, Member of Technology and Innovation Committee, CEO of Amdocs Management Limited and President of Amdocs Management Limited |
Amdocs Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amdocs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.071 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 10.15 B | |||
| Shares Outstanding | 116.5 M | |||
| Shares Owned By Institutions | 97.38 % | |||
| Number Of Shares Shorted | 1.89 M | |||
| Price To Earning | 19.03 X | |||
| Price To Book | 2.81 X |
Pair Trading with Amdocs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amdocs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amdocs will appreciate offsetting losses from the drop in the long position's value.Moving against Amdocs Stock
| 0.71 | EGIO | Edgio Inc Report 17th of July 2024 | PairCorr |
| 0.7 | NN | Nextnav Acquisition Corp Tech Boost | PairCorr |
| 0.56 | GB | Global Blue Group | PairCorr |
| 0.56 | VERI | Veritone Financial Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Amdocs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amdocs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amdocs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amdocs to buy it.
The correlation of Amdocs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amdocs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amdocs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amdocs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amdocs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Amdocs Stock please use our How to Invest in Amdocs guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Amdocs Stock analysis
When running Amdocs' price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Amdocs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amdocs. If investors know Amdocs will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amdocs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.18 | Dividend Share 1.74 | Earnings Share 4.68 | Revenue Per Share 41.665 | Quarterly Revenue Growth 0.05 |
The market value of Amdocs is measured differently than its book value, which is the value of Amdocs that is recorded on the company's balance sheet. Investors also form their own opinion of Amdocs' value that differs from its market value or its book value, called intrinsic value, which is Amdocs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amdocs' market value can be influenced by many factors that don't directly affect Amdocs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amdocs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amdocs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amdocs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.